Compare Costco Wholesale Corporation (COST) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs ResMed Inc. — how do they compare? Costco Wholesale Corporation trades at $946.92 (market cap $420.05B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Costco Wholesale Corporation is far larger — about 13.2× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and ResMed Inc. for 51 Days on average.
| COST | RMD | |
|---|---|---|
Market Cap | $420.05B | $31.89B |
Volume | 2,087,565 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $275.96 |
52-Week Low | $849.63 | $182.82 |
Typical Hold Time | 133 Days | 51 Days |
Enterprise Value | $407.33B | $31.24B |
Dividend Yield | 0.62% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $947.92, up 0.6% with strong technical momentum. The stock shows robust fundamentals with revenue growth from $275.24B in 2025 to projected $303.2B in 2026 and improving net margins. Recent March sales surged 11.3% year-over-year, while analyst consensus remains strongly bullish with 66% buy ratings and a $1,100 price target. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $954.
Outlook remains positive given membership fee increases and expansion potential, though high valuation multiples (P/E 45.66) pose risk if growth slows. Key risks include competitive pressures and economic sensitivity. Institutional accumulation continues with multiple advisors increasing positions in Q4 2025, supporting the bullish thesis.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
